AONs have emerged as promising therapeutic intervention for treatment of several inherited retinal diseases; two programs continued the investigations in clinical trials exploring the potency of AONs in rescuing the severe phenotypes of Leber congenital amaurosis 10 (LCA10) and USH2A-associated Usher syndrome and retinitis pigmentosa (RP), by applying sepofarsen and ultevursen, respectively. This evidence concerns the gene USH2A and retinitis pigmentosa.